PMID- 28459157
OWN - NLM
STAT- MEDLINE
DCOM- 20180301
LR  - 20180301
IS  - 1205-7541 (Electronic)
IS  - 0008-4212 (Linking)
VI  - 95
IP  - 7
DP  - 2017 Jul
TI  - Infliximab alleviates the mortality, mesenteric hypoperfusion, aortic 
      dysfunction, and multiple organ damage in septic rats.
PG  - 866-872
LID - 10.1139/cjpp-2016-0628 [doi]
AB  - Tumor necrosis factor-alpha (TNF-alpha) is a pivotal mediator that triggers 
      inflammatory process, oxidative stress, and multiple organ injury in sepsis. We 
      investigated the effects of infliximab on survival, mesenteric artery blood flow 
      (MBF), vascular reactivity, and oxidative and inflammatory injuries in cecal 
      ligation and puncture (CLP)-induced sepsis. Wistar rats were divided into Sham, 
      CLP, Sham+infliximab, and CLP+infliximab subgroups. Twenty-four hours before the 
      operations, rats were injected intraperitoneally with infliximab (7 mg/kg) or 
      vehicle (saline; 1 mL/kg). Twenty hours after the operations, MBF and 
      phenylephrine responses of isolated aortic rings were measured. Tissue damages 
      were examined biochemically and histopathologically. Furthermore, survival rates 
      were monitored throughout 96 h. Infliximab improved survival, mesenteric 
      perfusion, and aortic function after CLP. Increases of serum AST, ALT, LDH, BUN, 
      Cr, and inflammatory cytokines (tumor necrosis factor-alpha, interleukin-1 beta, 
      and interleukin-6) induced by CLP were blocked by infliximab. Infliximab 
      prevented malondialdehyde elevations in septic liver, lung, spleen, and kidney 
      tissues, as well as glutathione reductions in septic liver, spleen, and kidney 
      tissues. Protective effects of infliximab on multiple organ damage were also 
      observed histopathologically. Infliximab showed protective effects in sepsis due 
      to its improvement effects on mesenteric perfusion, aortic function, and its 
      anti-inflammatory and antioxidative effects.
FAU - Ozer, Erdem Kamil
AU  - Ozer EK
AD  - a Department of Pharmacology, Faculty of Medicine, Selcuk University, Konya, 
      Turkey.
FAU - Goktas, Mustafa Tugrul
AU  - Goktas MT
AD  - b Department of Pharmacology, Faculty of Medicine, Yildirim Beyazit University, 
      Ankara, Turkey.
FAU - Kilinc, Ibrahim
AU  - Kilinc I
AD  - c Department of Biochemistry, Faculty of Medicine, Necmettin Erbakan University, 
      Konya, Turkey.
FAU - Toker, Aysun
AU  - Toker A
AD  - c Department of Biochemistry, Faculty of Medicine, Necmettin Erbakan University, 
      Konya, Turkey.
FAU - Bariskaner, Hulagu
AU  - Bariskaner H
AD  - a Department of Pharmacology, Faculty of Medicine, Selcuk University, Konya, 
      Turkey.
FAU - Ugurluoglu, Ceyhan
AU  - Ugurluoglu C
AD  - d Department of Pathology, Faculty of Medicine, Selcuk University, Konya, Turkey.
FAU - Iskit, Alper Bektas
AU  - Iskit AB
AD  - e Department of Pharmacology, Faculty of Medicine, Hacettepe University, Ankara, 
      Turkey.
LA  - eng
PT  - Journal Article
DEP - 20170429
PL  - Canada
TA  - Can J Physiol Pharmacol
JT  - Canadian journal of physiology and pharmacology
JID - 0372712
RN  - 0 (Interleukin-6)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Animals
MH  - Aorta/*drug effects/physiopathology
MH  - Blood Circulation/*drug effects
MH  - Female
MH  - Infliximab/*pharmacology
MH  - Interleukin-6/metabolism
MH  - Mesentery/*blood supply
MH  - Multiple Organ Failure/*complications
MH  - Muscle Contraction/drug effects
MH  - Muscle, Smooth, Vascular/drug effects/physiopathology
MH  - Rats
MH  - Rats, Wistar
MH  - Sepsis/complications/*mortality/pathology/*physiopathology
OTO - NOTNLM
OT  - dysfonctionnement d'organes multiples
OT  - flux sanguin arteriel mesenterique
OT  - infliximab
OT  - mesenteric arterial blood flow
OT  - multiple organ dysfunction
OT  - reactivite vasculaire
OT  - sepsis
OT  - septicemie
OT  - survie
OT  - survival
OT  - vascular reactivity
EDAT- 2017/05/02 06:00
MHDA- 2018/03/02 06:00
CRDT- 2017/05/02 06:00
PHST- 2017/05/02 06:00 [pubmed]
PHST- 2018/03/02 06:00 [medline]
PHST- 2017/05/02 06:00 [entrez]
AID - 10.1139/cjpp-2016-0628 [doi]
PST - ppublish
SO  - Can J Physiol Pharmacol. 2017 Jul;95(7):866-872. doi: 10.1139/cjpp-2016-0628. 
      Epub 2017 Apr 29.